Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis
NCT07110844Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Oct 2031
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab in amyloid light chain amyloidosis. Started Nov 2025; status: recruiting.
02
Drugs
teclistamab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT07110844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110844.